Why Novo Nordisk Stock Just Popped

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered.

Why Hims & Hers Stock Just Got Destroyed

Everyones ganging up on Hims & Hers stock this week.

Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock plunges 27%

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

Market movers: Hims & Hers, Workday, Valaris, Monday.com...

Here are 10 things to watch in the stock market Monday

Shares of Eli Lilly and Novo Nordisk jumped in premarket trading after Hims & Hers said that the company will not sell its copycat weight-loss pill.

Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more

These are the stocks posting the largest moves in premarket trading.

Blitz-K.O. vor dem Super Bowl! Hims & Hers stoppt Billig-Wegovy nach massiven Drohungen der FDA!

Der Traum von der günstigen Abnehm-Pille ist vorerst geplatzt. Was als disruptiver Angriff auf das Milliarden-Monopol von Novo Nordisk und Eli Lilly begann, endete für den Telemedizin-Anbieter Hims &...

Hims & Hers scraps low-cost weight-loss pill following backlash

Hims & Hers scraps low-cost weight-loss pill following backlash Him & Hers (NYSE:HIMS) shares are set to open 23% lower at about $18 after the telehealth...

Hims & Hers Suddenly Pulls Its $49 Wegovy Copycat After FDA Threatens Action

The online telehealth company pulls the plug on its compound version of Novo Nordisks Wegovy drug in the wake of FDA commissioners warning

GLP-1 Envy Was Just the Beginning

A Super Bowl ad by Hims & Hers sells the idea that everyone should want to be billionaire-healthy.

Grails $700 blood test may detect cancer early with 2 tubes of blood

A new Super Bowl ad from Hims & Hers telehealth touts a blood test for cancer. Its $700, but its not a replacement for regular screening.

Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats

Telehealth company Hims & Hers cancels $49 monthly weight loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.

Hims & Hers stops selling weight loss pill days after unveiling it

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with stakeholders across the industry."

Hims & Hers drops plan for knockoff of Novo Nordisk’s new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug following the Food and Drug…

Hims & Hers drops plan for knockoff of Novo Nordisks new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug.

Hims & Hers drops plan for knockoff of Novo Nordisks new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug following the Food and Drug Administrations threat to restrict access to the ingredients needed to copy popular weight-loss medications. Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then th...

Hims & Hers drops plan for knockoff of Novo Nordisks new Wegovy weight loss pill

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug

Regulatory Scrutiny Puts Hims And Hers GLP 1 Growth Story To The Test

Hims & Hers Health (NYSE:HIMS) is facing heightened regulatory and legal scrutiny over its compounded semaglutide weight loss pill, launched as a lower cost alternative to Wegovy.The FDA has issued public statements targeting unapproved compounded GLP-1 drugs and has specifically referenced Hims & Hers in this context.The Department of Health and Human Services has referred Hims & Hers to the Department of Justice for a potential investigation into federal law compliance.Novo Nordisk is...

Hims & Hers scraps copycat Wegovy weight-loss pill after probe

The announcement comes a day after the US Food and Drug Administration said it was cracking down on copycat weight-loss treatments.

Hims & Hers Health to stop offering copycat Wegovy pill

Hims & Hers will stop selling compounded version of Novo’s obesity pill

Hims & Hers will stop selling what it claims to be a cheaper, compounded version of Novo Nordisks obesity pill on its telehealth platform.

Hims & Hers pulls copycat weight-loss pill after threats of legal action

Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.

Hims & Hers to Stop Offering Copycat Wegovy Weight-Loss Pill

Just two days after launching a copycat version of the new Wegovy weight-loss pill, Hims & Hers Health Inc. said it will stop selling the drug.

Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown

Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.

Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown

Feb 7 () - Hims & Hers said ?in a statement ?on Saturday that it will ?stop offering ?access to the ?compounded semaglutide pill after the U. Food ?and Drug Administration said it would take action ?against the telehealth provider for its $49 weight-loss ?pill.

Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown By Reuters

Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown

U.S. signals crackdown on compounded weight-loss drugs; Hims shares tumble

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

HHS asks Justice Department to probe Hims & Hers over its cheaper compounded version of Wegovy

FDA will take “decisive steps” to thwart companies from mass marketing unapproved, compounded versions of GLP-1 drugs

FDA to restrict GLP-1 ingredients used in non?approved compounded drugs

The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims & Hers.

FDA to Restrict Copycat Weight Loss Drugs Sold by Pharma Rivals

The US Food and Drug Administration said it would crack down on copycat weight loss drugs like those marketed by Hims & Hers Health Inc.